The GVP framework

Pharmacovigilance (PV) is the core post-market safety institution. China's Good Pharmacovigilance Practice (GVP), issued in 2021, moved the system from "adverse-reaction reporting" into full-lifecycle pharmacovigilance.

  • Drug Administration Law, Art. 79–83 — adverse-reaction monitoring and reporting
  • GVP — technical standard for the PV system
  • Measures for Adverse Drug Reaction Reporting and Monitoring

Core GVP requirements

System architecture

  • Independent PV function: with sufficient dedicated staff of medical/pharmacy/epidemiology background.
  • PV responsible person: designated to run and ensure compliance of the system.
  • PSMF: the pharmacovigilance system master file.
  • Reporting channels: hotline, website, literature and regulator feedback.

Adverse-reaction reporting duties

  • Serious adverse reactions: reported within 15 days; deaths immediately.
  • Other reactions: within 30 days.
  • Serious reactions abroad: also reportable to Chinese authorities in time.
  • Periodic Safety Update Reports (PSUR): submitted on schedule.

Legal risk warning: failure to report adverse reactions is among the most common GMP/GVP inspection defects. Consequences run from warnings to fines of CNY 50,000–500,000, and in serious cases suspension or revocation of the approval document. Drug Administration Law Art. 134 provides aggravated penalties for holders that fail to monitor or report.

Post-authorization safety studies (PASS)

  • Mandatory PASS: required by the authority (e.g. confirmatory studies for conditionally approved drugs) — failure leads to revocation.
  • Voluntary PASS: sponsor-initiated safety studies.
  • Compliance: prospective patient-data collection must also satisfy GCP, ethics review, informed consent and possibly HGR approval/filing.

Product recall

Recall is a statutory MAH obligation when a marketed drug has quality problems or safety hazards. Three tiers by severity:

  • Grade 1 (serious health hazard): notify users and report within 24 hours.
  • Grade 2 (temporary or reversible harm): within 48 hours.
  • Grade 3 (no health hazard, recalled for other reasons): within 72 hours.

Product liability — civil damages

Where a drug defect injures a patient, the victim may claim damages from the MAH (or manufacturer/seller) under the Civil Code and Product Quality Law.

  • Strict liability: the victim need only prove (a) a defect, (b) damage, and (c) causation — not fault.
  • Three defect types: manufacturing defects (e.g. contamination), design defects (unreasonable danger in the drug itself), and warning defects (inadequate labelling of known risks).
  • Punitive damages: Drug Administration Law Art. 144 permits 10× the price or 3× the loss for producing/selling counterfeit or substandard drugs.

How we help

  1. GVP system building: PSMF drafting, SOPs and staff training.
  2. Adverse-event legal support: assessing reporting duties, preparing filings and shaping external communications.
  3. Recall support: tier judgement, recall-plan drafting and review, and regulator communication.
  4. Product-liability disputes: investigation, negotiation and litigation defence.
  5. GVP audits: pre-inspection self-audit and remediation.